Antibody drug conjugate: the “biological missile” for targeted cancer therapy

Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Zhiwen, Li, Shijun, Han, Sifei, Shi, Chen, Zhang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941077/
https://www.ncbi.nlm.nih.gov/pubmed/35318309
http://dx.doi.org/10.1038/s41392-022-00947-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941077/
https://www.ncbi.nlm.nih.gov/pubmed/35318309
http://dx.doi.org/10.1038/s41392-022-00947-7

Ejemplares similares